Vimarsana
Biggest News Aggregation in the World

Page 38 - Ir Team News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Ir Team. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Ir Team Today - Breaking & Trending Today

Junshi Biosciences Announces Acceptance by NMPA of - Vimarsana News

Junshi Biosciences Announces Acceptance by NMPA of

Junshi Biosciences Announces Acceptance by NMPA of Supplemental New Drug Application for Toripalimab Plus Chemotherapy as First-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma July 29, 2021 20:40 ET | Source: Junshi Biosciences Junshi Biosciences Shanghai, CHINA SHANGHAI, China, July 30, 2021 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced today that the Na...

Junshi Biosciences Announces Acceptance by NMPA of Supplemental New Drug Application for Toripalimab Plus Chemotherapy as First-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma - Vimarsana News

Junshi Biosciences Announces Acceptance by NMPA of Supplemental New Drug Application for Toripalimab Plus Chemotherapy as First-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma

(1) SHANGHAI, China, July 30, 2021 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced today that the National Medical Products Administration (NMPA) of China has accepted its supplemental New Drug Application (sNDA) for toripalimab in combination with platinum-containing chemotherapy as the first-line treatment for patients with locally advanced or metastatic esophageal squamous cell carcinoma (ESCC). It is the fifth NDA submitted for...

Junshi Biosciences Announces Acceptance by NMPA of Supplemental New Drug Application for ... - Vimarsana News

Junshi Biosciences Announces Acceptance by NMPA of Supplemental New Drug Application for ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Junshi Biosciences Announces Acceptance by NMPA of Supplemental New Drug Application for ... Junshi BiosciencesJuly 30, 2021 GMT SHANGHAI, China, July 30, 2021 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced today that the National Medical Products Administration (NMPA) of China has accepted its supplemental New Drug Application (sNDA) fo...

Source: apnews.com
Junshi Biosciences and Immorna Announce Joint Venture to Develop Innovative Self-Replicating and Conventional mRNA Therapeutics and Vaccines | Comunicados | Edición USA - Vimarsana News

Junshi Biosciences and Immorna Announce Joint Venture to Develop Innovative Self-Replicating and Conventional mRNA Therapeutics and Vaccines | Comunicados | Edición USA

20 jul 2021 Junshi Biosciences and Immorna Announce Joint Venture to Develop Innovative Self-Replicating and Conventional mRNA Therapeutics and Vaccines SHANGHAI, China, July 20, 2021 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced today that the company has established a joint venture with Immorna, a fast-growing biotechnology company focusing on the process development and optimization of mRNA and delivery vehicles and the res...

Source: efe.com
Junshi Biosciences and Immorna Announce Joint Venture to - Vimarsana News

Junshi Biosciences and Immorna Announce Joint Venture to

Junshi Biosciences and Immorna Announce Joint Venture to Develop Innovative Self-Replicating and Conventional mRNA Therapeutics and Vaccines July 19, 2021 20:41 ET | Source: Junshi Biosciences Junshi Biosciences Shanghai, CHINA SHANGHAI, China, July 20, 2021 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced today that the company has established a joint venture with Immorna, a fast-grow...